Loyola University Stritch SOM, Maywood, Illinois, 1995
After receiving his Ph.D. in Molecular and Cellular Biochemistry from Loyola University of Chicago, Dr. Tentler was recruited to the University of Colorado Denver in 1995 as a post-doctoral fellow in the laboratory of Dr. Arthur Gutierrez-Hartmann, M.D., in the Division of Endocrinology, Metabolism and Diabetes. He was promoted to Instructor in 1998 and then to Assistant Professor in 2003 in the Department of Medicine. In September 2007, he joined the faculty of the Division of Medical Oncology in the Developmental Therapeutics/GI laboratory. under the directorship of S. Gail Eckhardt, M.D., Division Head, Medical Oncology.
John Tentler, PhD
As part of the Developmental Therapeutics/GI Laboratory at UCD, my research is focused on pre-clinical studies of novel, rationally-based drugs for the treatment of advanced colorectal cancer, utilizing both cell culture and in vivo mouse model systems. These studies serve as a basis for therapeutic treatment options/choices for patients with advanced GI cancers in the UC Phase I Clinical Trials Program.
Eckel, K., Tentler, J., Capetta, G., Diamond, S. Gutierrez-Hartmann, A. The Epithelial-Specific ETS Transcription Factor ESX/ESE-1/Elf-3 Modulates Breast Cancer-Associated Gene Expression. DNA Cell Biol. Feb;22(2):79-94 2003.
Schedin PJ, Eckel-Mahan KL, McDaniel SM, Prescott JD, Brodsky KS, Tentler JJ, Gutierrez-Hartmann A. ESX induces transformation and functional epithelial to mesenchymal transition in MCF-12A mammary epithelial cells. Oncogene. Mar 4;23(9):1766-79 2004.
Pending grant applications:
UCHSC Department of Medicine Grant
NIH R21 Grant